The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.

Saved in:

Bibliographic Details
Title:	The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Authors:	Latva-Rasku, Aino¹, Honka, Miikka-Juhani¹, Kullberg, Joel^2,3, Mononen, Nina⁴, Lehtimäki, Terho⁴, Saltevo, Juha⁵, Kirjavainen, Anna K.¹, Saunavaara, Virva¹, Iozzo, Patricia⁶, Johansson, Lars², Oscarsson, Jan⁷, Hannukainen, Jarna C.¹, Nuutila, Pirjo^1,8 pirjo.nuutila@utu.fi
Source:	Diabetes Care. May2019, Vol. 42 Issue 5, p931-937. 7p.
Database:	Academic Search Ultimate

Description
ISSN:	01495992
DOI:	10.2337/dc18-1569